Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omidenepag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 20/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omidenepag SCHEMBL533245 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL30433956 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL533632 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL22364205 | 0.89 | PTGER2 (0.81) | PTGER2PTGER4 | |
| SCHEMBL534263 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL30434740 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL15414827 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL29375346 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL22283788 | 0.88 | PTGER2 (0.79) | PTGER2PTGER4 | |
| SCHEMBL533704 | 0.88 | PTGER2 (0.79) | PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-06 | — | — | US | claimed |
| CN-118084895-A | Nitric oxide donor Omidenepag derivative and preparation method and application thereof | 中国药科大学 | 2024-05-28 | — | — | CN | claimed |
| US-20230404988-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | MEDETIA (FR) | 2023-12-21 | — | — | US | claimed |
| US-20230277515-A1 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-09-07 | — | — | US | claimed |
| EP-4225319-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | Medetia (FR) | 2023-08-16 | — | — | EP | claimed |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | claimed |
| WO-2022074150-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | MEDETIA (FR) | 2022-04-14 | — | — | WO | claimed |
| EP-3981410-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | Medetia (FR) | 2022-04-13 | — | — | EP | claimed |
| CN-118084895-B | Nitric oxide donor Omidenepag derivative and preparation method and application thereof | 中国药科大学 | 2025-09-05 | — | — | CN | disclosed |
| CN-118084895-B | Nitric oxide donor Omidenepag derivative and preparation method and application thereof | 中国药科大学 | 2025-09-05 | — | — | CN | disclosed |
| WO-2025180071-A1 | NITRIC OXIDE DONOR TYPE OMIDENPAG DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2025-09-04 | — | — | WO | disclosed |
| WO-2025180071-A1 | NITRIC OXIDE DONOR TYPE OMIDENPAG DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2025-09-04 | — | — | WO | disclosed |
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-06 | — | — | US | disclosed |
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-06 | — | — | US | disclosed |
| JP-2023110029-A | Omidenepag combination | 参天製薬株式会社 | 2023-08-08 | — | — | JP | disclosed |
| JP-2023110029-A | Omidenepag combination | 参天製薬株式会社 | 2023-08-08 | — | — | JP | disclosed |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
| WO-2022074150-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | MEDETIA (FR) | 2022-04-14 | — | — | WO | disclosed |
| EP-3981410-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | Medetia (FR) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12290511-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
| US-11666563-B2 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
| US-20230404988-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | PTGER4, PTGER2, PTGER1 | PTGER2 2/4885PTGER4 1/4885 |
| US-20230277515-A1 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | PTGIS, AASDHPPT, AGT | PTGER2 121/4885PTGER4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.